185 related articles for article (PubMed ID: 28262569)
1. Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection.
Waters V; Yau Y; Beaudoin T; Wettlaufer J; Tom SK; McDonald N; Rizvi L; Klingel M; Ratjen F; Tullis E
J Cyst Fibros; 2017 Jul; 16(4):492-495. PubMed ID: 28262569
[TBL] [Abstract][Full Text] [Related]
2. Two case reports of the successful eradication of new isolates of Burkholderia cepacia complex in children with cystic fibrosis.
Kitt H; Lenney W; Gilchrist FJ
BMC Pharmacol Toxicol; 2016 Mar; 17():14. PubMed ID: 27018049
[TBL] [Abstract][Full Text] [Related]
3. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
[TBL] [Abstract][Full Text] [Related]
4. Combination aerosol therapy to treat Burkholderia cepacia complex.
Middleton PG; Kidd TJ; Williams B
Eur Respir J; 2005 Aug; 26(2):305-8. PubMed ID: 16055880
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
Blumer JL; Saiman L; Konstan MW; Melnick D
Chest; 2005 Oct; 128(4):2336-46. PubMed ID: 16236892
[TBL] [Abstract][Full Text] [Related]
6. Activity of Tobramycin against Cystic Fibrosis Isolates of Burkholderia cepacia Complex Grown as Biofilms.
Kennedy S; Beaudoin T; Yau YC; Caraher E; Zlosnik JE; Speert DP; LiPuma JJ; Tullis E; Waters V
Antimicrob Agents Chemother; 2016 Jan; 60(1):348-55. PubMed ID: 26503664
[TBL] [Abstract][Full Text] [Related]
7. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
[TBL] [Abstract][Full Text] [Related]
8. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
Al-Aloul M; Nazareth D; Walshaw M
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
[TBL] [Abstract][Full Text] [Related]
9. Infection with Burkholderia cepacia complex bacteria and pulmonary exacerbations of cystic fibrosis.
St Denis M; Ramotar K; Vandemheen K; Tullis E; Ferris W; Chan F; Lee C; Slinger R; Aaron SD
Chest; 2007 Apr; 131(4):1188-96. PubMed ID: 17426227
[TBL] [Abstract][Full Text] [Related]
10. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
11. Can Burkholderia cepacia complex be eradicated with nebulised amiloride and TOBI?
Ball R; Brownlee KG; Duff AJ; Denton M; Conway SP; Lee TW
J Cyst Fibros; 2010 Jan; 9(1):73-4. PubMed ID: 19932062
[No Abstract] [Full Text] [Related]
12. An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosa.
Sutharsan S; Naehrig S; Mellies U; Sieder C; Ziegler J
BMC Pulm Med; 2020 Jun; 20(1):167. PubMed ID: 32532226
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L
Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882
[TBL] [Abstract][Full Text] [Related]
14. Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients.
Garcia BA; Carden JL; Goodwin DL; Smith TA; Gaggar A; Leon K; Antony VB; Rowe SM; Solomon GM
BMC Pulm Med; 2018 Feb; 18(1):35. PubMed ID: 29444656
[TBL] [Abstract][Full Text] [Related]
15. Management of initial colonisations with Burkholderia species in France, with retrospective analysis in five cystic fibrosis Centres: a pilot study.
Gruzelle V; Guet-Revillet H; Segonds C; Bui S; Macey J; Chiron R; Michelet M; Murris-Espin M; Mittaine M
BMC Pulm Med; 2020 Jun; 20(1):159. PubMed ID: 32503487
[TBL] [Abstract][Full Text] [Related]
16. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
Moriarty TF; McElnay JC; Elborn JS; Tunney MM
Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
[TBL] [Abstract][Full Text] [Related]
17. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
Konstan MW; Flume PA; Kappler M; Chiron R; Higgins M; Brockhaus F; Zhang J; Angyalosi G; He E; Geller DE
J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG
Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974
[TBL] [Abstract][Full Text] [Related]
19. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial.
Galeva I; Konstan MW; Higgins M; Angyalosi G; Brockhaus F; Piggott S; Thomas K; Chuchalin AG
Curr Med Res Opin; 2013 Aug; 29(8):947-56. PubMed ID: 23672633
[TBL] [Abstract][Full Text] [Related]
20. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL
J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
